Luminex reported the renewal and expansion of Invitrogen’s license and supply agreement for its multiplexed analyte detection technology and systems. The new deal extends the license and provides Invitrogen with access to Luminex’ multiplex detection platforms.
xMAP® technology and Luminex instrument platforms use proprietary microspheres encoded with combinations of spectrally distinct fluorescent dyes to determine the relative concentrations of different proteins or peptides at the same time in the same sample. Invitrogen, which offers more than 200 assays based on xMAP technology, also has a large number of new multiplexed assays in its product development pipeline to expand the number of targets accessible to scientists, according to the company.
